<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title><![CDATA[Health & Pharma News | Latest Healthcare Stories]]></title><description><![CDATA[Health & Pharma News | Latest Healthcare Stories]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/</link><image><url>https://www.reuters.com/pf/resources/icons/favicon.ico?d=108</url><title>Health &amp; Pharma News | Latest Healthcare Stories</title><link>https://www.reuters.com/business/healthcare-pharmaceuticals/</link></image><generator>https://rss.app</generator><lastBuildDate>Thu, 18 Aug 2022 18:06:22 GMT</lastBuildDate><atom:link href="https://rss.app/feeds/4pMExRIWVbRAE7DQ.xml" rel="self" type="application/rss+xml"/><language><![CDATA[en]]></language><item><title><![CDATA[Health & Pharma News | Latest Healthcare Stories ]]></title><description><![CDATA[<div><img src="https://www.reuters.com/pf/resources/images/reuters/reuters-default.png?d=108" style="width: 100%;" /><div>Find latest healthcare news from every corner of the globe at Reuters.com, your online source for breaking international news coverage.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/</link><guid isPermaLink="false">4d9cd84ac768cf056e70760be2418401</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Thu, 18 Aug 2022 17:12:36 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/pf/resources/images/reuters/reuters-default.png?d=108"/></item><item><title><![CDATA[Factbox: Latest on the worldwide spread of the coronavirus]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/iXf21B5Wpa9b55mrNFfupcmlmzw=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/Y7KLLKFH7BJTBH6DMF4MI4KTAU.jpg" style="width: 100%;" /><div>The World Health Organization on Thursday recommended the use of French drugmaker Valneva's COVID-19 vaccine.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/latest-worldwide-spread-coronavirus-2022-01-03/</link><guid isPermaLink="false">b6f0dccb2aa42ae8af9ba59430e2c931</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Thu, 18 Aug 2022 15:20:32 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/iXf21B5Wpa9b55mrNFfupcmlmzw=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/Y7KLLKFH7BJTBH6DMF4MI4KTAU.jpg"/></item><item><title><![CDATA[WHO recommends Valneva's COVID vaccine]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/g5j_Kk5HsYM1FOld-Kem9G9om6c=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/SKVGLVNPJ5MXLPG2LHTZXYNAHQ.jpg" style="width: 100%;" /><div>The World Health Organization (WHO) on Thursday recommended the use of French drugmaker Valneva's COVID-19 vaccine.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/who-recommends-valnevas-covid-vaccine-2022-08-18/</link><guid isPermaLink="false">0609f916c497c831c6e95f855b6d82c5</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Thu, 18 Aug 2022 13:45:48 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/g5j_Kk5HsYM1FOld-Kem9G9om6c=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/SKVGLVNPJ5MXLPG2LHTZXYNAHQ.jpg"/></item><item><title><![CDATA[Factbox: Monkeypox cases and deaths around the world]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/hvIk9X57woOIXWk0s3wUwidjTvE=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/ZIPTTC4MYBJOLDNPUG2775TG4E.jpg" style="width: 100%;" /><div>More than 80 countries where monkeypox is not endemic have reported outbreaks of the viral disease, which the World Health Organization has declared a global health emergency, as confirmed cases crossed 38,800 and non-endemic countries reported their first related deaths.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/monkeypox-cases-around-world-2022-05-23/</link><guid isPermaLink="false">dcf9d5ec8a8fad5e0a05c01c92911b5c</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Thu, 18 Aug 2022 13:45:07 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/hvIk9X57woOIXWk0s3wUwidjTvE=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/ZIPTTC4MYBJOLDNPUG2775TG4E.jpg"/></item><item><title><![CDATA[Germany's constitutional court upholds measles vaccine mandate for children]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/K1WZZsNktNFoE3Oam2KyfPlLi0g=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/HFK4OGWYA5K2PMJQY2GZC7WQAI.jpg" style="width: 100%;" /><div>The German constitutional court upheld the country's measles vaccine mandate for children on Thursday, ruling against a challenge brought by parents.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/germanys-constitutional-court-upholds-measles-vaccine-mandate-children-2022-08-18/</link><guid isPermaLink="false">40c010296211ce9af61e9838eeb1a62b</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Thu, 18 Aug 2022 08:04:22 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/K1WZZsNktNFoE3Oam2KyfPlLi0g=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/HFK4OGWYA5K2PMJQY2GZC7WQAI.jpg"/></item><item><title><![CDATA[U.S. FDA approves bluebird bio's gene therapy for rare blood disorder]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/NxRv1Ug7wNLzDw9qngtsQ3JFP1k=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/RPCCRUWPGJMABEIJ2J7KN3LSSI.jpg" style="width: 100%;" /><div>The U.S. Food and Drug Administration on Wednesday approved bluebird bio's gene therapy for the treatment of a rare blood disorder.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-bluebird-bios-gene-therapy-rare-blood-disorder-2022-08-17/</link><guid isPermaLink="false">5abdce635ed0825f5ac725f525b22551</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Wed, 17 Aug 2022 18:08:31 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/NxRv1Ug7wNLzDw9qngtsQ3JFP1k=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/RPCCRUWPGJMABEIJ2J7KN3LSSI.jpg"/></item><item><title><![CDATA[Russia's daily COVID cases cross 30,000 for first time since mid-March]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/7BPQe86xBsXSLknCjoKY7SlI4PQ=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/EV2DSDSSFVON5HUUOA7YLL5Y6Y.jpg" style="width: 100%;" /><div>Russia reported 33,106 new daily coronavirus cases on Wednesday, authorities said, the highest figure since mid-March this year.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/russias-daily-covid-cases-cross-30000-first-time-since-mid-march-2022-08-17/</link><guid isPermaLink="false">971c5beb099de5bca9a3255d3b4dd77a</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Wed, 17 Aug 2022 17:29:51 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/7BPQe86xBsXSLknCjoKY7SlI4PQ=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/EV2DSDSSFVON5HUUOA7YLL5Y6Y.jpg"/></item><item><title><![CDATA[Sanofi trial failure halts work on breast cancer treatment amcenestrant]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/VBj8eypHcsyEhrv6ql-uvkJe-Vw=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/TPHY3HC55ZLHBALC5SCENCBNXA.jpg" style="width: 100%;" /><div>Sanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company's development prospects.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-ends-development-amcenestrant-breast-cancer-treatment-2022-08-17/</link><guid isPermaLink="false">b5075f75839ace1246b36f559d636b53</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Wed, 17 Aug 2022 17:12:11 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/VBj8eypHcsyEhrv6ql-uvkJe-Vw=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/TPHY3HC55ZLHBALC5SCENCBNXA.jpg"/></item><item><title><![CDATA[FDA says faulty Philips device reports accelerating as CEO departs]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/9_Z_7cpitKIJ5-L1t18uz8pm82o=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/IMG3FSBHNFLRFM5FWXDM3JKIOE.jpg" style="width: 100%;" /><div>The U.S. Food and Drug Administration (FDA) said reports of faulty Philips ventilators and sleep apnea machines had risen in the past quarter, underlining problems facing the Dutch company, which has just announced plans to replace its CEO.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/fda-says-faulty-philips-device-reports-accelerating-ceo-departs-2022-08-17/</link><guid isPermaLink="false">ceb8d753722221e177923336f22e97d1</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Wed, 17 Aug 2022 17:01:10 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/9_Z_7cpitKIJ5-L1t18uz8pm82o=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/IMG3FSBHNFLRFM5FWXDM3JKIOE.jpg"/></item><item><title><![CDATA[Takeda's dengue vaccine expected to be approved in Indonesia soon -Nikkei]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/Yq5dRbtnmK9xjJP38Dqv7izjo9g=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/FIVPR75H6BO6JCG25AHJ4HHUW4.jpg" style="width: 100%;" /><div>Takeda Pharmaceutical Co's experimental vaccine for dengue fever is expected to be approved in Indonesia soon, Japan's Nikkei newspaper reported on Wednesday.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/takedas-dengue-vaccine-expected-be-approved-indonesia-soon-nikkei-2022-08-17/</link><guid isPermaLink="false">541a0e2a7f542812dc4d110e61a1f2ee</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Wed, 17 Aug 2022 09:17:38 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/Yq5dRbtnmK9xjJP38Dqv7izjo9g=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/FIVPR75H6BO6JCG25AHJ4HHUW4.jpg"/></item><item><title><![CDATA[Baby formula supplies improving, say U.S. retailers Walmart and Target]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/43MizTeh9d-K_yDXalOQLAUQwew=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/CAUUFMYEABLFVEOYONBI5WC7KM.jpg" style="width: 100%;" /><div>Two big U.S. retailers Walmart Inc and Target Corp said on Tuesday that supplies of baby formula were improving, months after the country faced acute shortages that had caused a panic among parents.</div></div>]]></description><link>https://www.reuters.com/business/retail-consumer/walmart-says-baby-formula-availability-improving-its-stores-2022-08-16/</link><guid isPermaLink="false">a193e17da2d83aa1202a30d2a54791de</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Tue, 16 Aug 2022 21:09:47 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/43MizTeh9d-K_yDXalOQLAUQwew=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/CAUUFMYEABLFVEOYONBI5WC7KM.jpg"/></item><item><title><![CDATA[Sanofi launches global health brand with non-profit treatments]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/-FFAT6sjMKVWQuJd07d1D0of7A4=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/R6O4GRAAVVNTJNJ4HMNWYEIPNQ.jpg" style="width: 100%;" /><div>French drugmaker Sanofi will make 30 of its treatments, including insulin, available on a not-for-profit basis in 40 lower-income countries in the first step of its plan to increase access to its medicines worldwide.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-launches-global-health-brand-with-non-profit-treatments-2022-07-04/</link><guid isPermaLink="false">10202383f7391d8121265e3edfb3d629</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Mon, 04 Jul 2022 10:14:58 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/-FFAT6sjMKVWQuJd07d1D0of7A4=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/R6O4GRAAVVNTJNJ4HMNWYEIPNQ.jpg"/></item><item><title><![CDATA[Eastern China cities tighten COVID curbs as new clusters emerge]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/M3OjriszY0Ktkw2IUL4cfPneHUo=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/4CSWH4FOJBK3XKUK4WYV55MCJA.jpg" style="width: 100%;" /><div>Cities in eastern China tightened COVID-19 curbs on Sunday as coronavirus clusters emerge, posing a new threat to China's economic recovery under the government's strict zero-COVID policy.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-wuxi-tightens-covid-curbs-new-clusters-emerge-2022-07-03/</link><guid isPermaLink="false">280435487d0af40528bbea0bb7b9c394</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Mon, 04 Jul 2022 00:22:44 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/M3OjriszY0Ktkw2IUL4cfPneHUo=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/4CSWH4FOJBK3XKUK4WYV55MCJA.jpg"/></item><item><title><![CDATA[German health minister in move to boost use of COVID treatment Paxlovid]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/_iUsKtwwEo6KIwN8YaLX362ildk=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/53HHGVRZUFLLBHIRJNCBPT6RDY.jpg" style="width: 100%;" /><div>Germany's health minister said on Sunday he will push for more prescriptions of Pfizer's oral COVID-19 antiviral treatment Paxlovid by family doctors to reduce severe cases of the disease.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/german-health-minister-move-boost-use-covid-treatment-paxlovid-2022-07-03/</link><guid isPermaLink="false">6a16f2ace420ac39714780786907545c</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Sun, 03 Jul 2022 14:53:32 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/_iUsKtwwEo6KIwN8YaLX362ildk=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/53HHGVRZUFLLBHIRJNCBPT6RDY.jpg"/></item><item><title><![CDATA[Monkeypox symptoms differ from previous outbreaks ]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/ELZ-dxgnkTMDYE7rvEvYs-tSwz0=/300x157/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/HSK6NS5OTFK75AD5DNQXT63ENI.jpg" style="width: 100%;" /><div>Patients with monkeypox in the UK have noticeably different symptoms from those seen in previous outbreaks, according to researchers in London, raising concerns cases are being missed.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/monkeypox-symptoms-differ-previous-outbreaks-uk-study-2022-07-01/</link><guid isPermaLink="false">babd5e954a7706afb7725ed090967e96</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Sat, 02 Jul 2022 01:14:23 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/ELZ-dxgnkTMDYE7rvEvYs-tSwz0=/300x157/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/HSK6NS5OTFK75AD5DNQXT63ENI.jpg"/></item><item><title><![CDATA[Omicron-specific COVID shots could increase protection as boosters, European Medicines Agency says]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/hUyCaHXjfJ2y5V9RQoiChMf0qj0=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/SPZ6OJT4D5IO5MVJLVLRYMKRT4.jpg" style="width: 100%;" /><div>Coronavirus vaccines tweaked to include the Omicron variant strain can improve protection when used as a booster, the European Medicines Agency and other global health regulators said on Friday.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/modified-mrna-covid-shots-could-increase-protection-boosters-ema-2022-07-01/</link><guid isPermaLink="false">617c8b3fcb39ff55c2794e49cef0f7bf</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Fri, 01 Jul 2022 20:26:43 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/hUyCaHXjfJ2y5V9RQoiChMf0qj0=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/SPZ6OJT4D5IO5MVJLVLRYMKRT4.jpg"/></item><item><title><![CDATA[Novavax expects COVID vaccine targeting Omicron in fourth quarter]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/gBB-5U6H9oy5EpREuvWFEOsSWP8=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/DLDRFZMDSBIHVKS6TE4BBZRMTQ.jpg" style="width: 100%;" /><div>Novavax Inc said on Friday it expects to provide a COVID-19 vaccine targeting Omicron in the fourth quarter as it accelerates development of shots to protect against the BA.4 and BA.5 subvariants.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-expects-covid-vaccine-targeting-omicron-fourth-quarter-2022-07-01/</link><guid isPermaLink="false">1c4981a07ca24f72190ba1fe6168ec06</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Fri, 01 Jul 2022 20:24:24 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/gBB-5U6H9oy5EpREuvWFEOsSWP8=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/DLDRFZMDSBIHVKS6TE4BBZRMTQ.jpg"/></item><item><title><![CDATA[U.S. orders 2.5 million more doses of Bavarian Nordic's vaccine for monkeypox]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/OHrPB6awf8npev1m0ENOrJ472Gw=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/FC7SJHNQANJXDNIQDHROU4N5KM.jpg" style="width: 100%;" /><div>The U.S. government has ordered 2.5 million more doses of Bavarian Nordic's vaccine for use against monkeypox outbreaks, the Department of Health and Human Services said on Friday.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/us-orders-25-mln-more-doses-bavarian-nordics-vaccine-monkeypox-2022-07-01/</link><guid isPermaLink="false">dd41cbf09b49741e66ce21fd0025ca3a</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Fri, 01 Jul 2022 15:01:19 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/OHrPB6awf8npev1m0ENOrJ472Gw=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/FC7SJHNQANJXDNIQDHROU4N5KM.jpg"/></item><item><title><![CDATA[Oxford Biomedica signs new deal to make AstraZeneca COVID shot]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/7HW8US2sodj0vqpAeVtk2acoyxI=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/NICSUZLWEJNSRDGFXS66T57BRU.jpg" style="width: 100%;" /><div>Britain's Oxford Biomedica said on Friday it had signed a new three-year agreement to potentially make AstraZeneca's COVID-19 vaccine beyond 2022, but no volumes were defined in an indication of waning demand for the shot.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/oxford-biomedica-signs-new-deal-make-astrazeneca-covid-shot-2022-07-01/</link><guid isPermaLink="false">18e6a57a687f5b673ab3a8030221f48f</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Fri, 01 Jul 2022 06:54:16 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/7HW8US2sodj0vqpAeVtk2acoyxI=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/NICSUZLWEJNSRDGFXS66T57BRU.jpg"/></item><item><title><![CDATA[North Korea blames 'alien things' near border with South for COVID outbreak]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/ColZI84u_7UsjqfHMDE9gI4xIcA=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/7SLUGH7MJFOTLLZWMJXNFWGP7Y.jpg" style="width: 100%;" /><div>North Korea claimed that the country's first COVID outbreak began with patients touching "alien things" near the border with South Korea, apparently shifting blame to the neighbour.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/nkorea-says-covid-outbreak-began-with-patients-touching-alien-things-near-border-2022-06-30/</link><guid isPermaLink="false">749bee407a2a6ecadf15c6fca9935f19</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Fri, 01 Jul 2022 04:47:46 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/ColZI84u_7UsjqfHMDE9gI4xIcA=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/7SLUGH7MJFOTLLZWMJXNFWGP7Y.jpg"/></item><item><title><![CDATA[US FDA wants COVID boosters targeting Omicron BA.4, BA.5 subvariants]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/AVQm4NDNeaka3qe6fFtXP2EAYzE=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/OV2PC52TJZNG5PW4JK4QPO2EU4.jpg" style="width: 100%;" /><div>The U.S. Food and Drug Administration on Thursday recommended COVID-19 vaccine manufacturers change the design of their booster shots beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants of the coronavirus.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/fda-recommends-inclusion-ba4-ba5-subvariants-covid-boosters-2022-06-30/</link><guid isPermaLink="false">575fbd924bd75b01edcd686830fe612c</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Fri, 01 Jul 2022 02:09:36 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/AVQm4NDNeaka3qe6fFtXP2EAYzE=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/OV2PC52TJZNG5PW4JK4QPO2EU4.jpg"/></item><item><title><![CDATA[U.S. FDA to use existing Omicron booster data to review shots targeting new subvariants -official]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/N-uzRLXT7bxkFCCGTuSbPWmN7hg=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/HYZQFANFPFPXJDYFU7YX35WQFQ.jpg" style="width: 100%;" /><div>U.S. health regulators will not require companies to submit new clinical trial data on COVID-19 vaccines that target the now dominant BA.4 and BA.5 Omicron subvariants to authorize those shots, but will instead rely on studies showing the efficacy of targeting the earlier BA.1 subvariant, a top official said on Thursday.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/fda-will-not-require-clinical-trial-data-authorize-redesigned-covid-boosters-2022-06-30/</link><guid isPermaLink="false">30c56ddd181c27a82c71453b2ecdeea3</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Thu, 30 Jun 2022 23:16:13 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/N-uzRLXT7bxkFCCGTuSbPWmN7hg=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/HYZQFANFPFPXJDYFU7YX35WQFQ.jpg"/></item><item><title><![CDATA[Pausing methotrexate improves booster response; first-trimester of pregnancy vaccination most beneficial]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/0USrPCvsPYn0KzVUQOqwO3RaKOI=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/HFGSJMUK6NI25EXOEMGKHHGDSE.jpg" style="width: 100%;" /><div>The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/pausing-methotrexate-improves-booster-response-first-trimester-pregnancy-2022-06-30/</link><guid isPermaLink="false">7a8e068ed00a73b0ebd2eb0deba1bd30</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Thu, 30 Jun 2022 18:36:41 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/0USrPCvsPYn0KzVUQOqwO3RaKOI=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/HFGSJMUK6NI25EXOEMGKHHGDSE.jpg"/></item><item><title><![CDATA[AstraZeneca says Imfinzi combo shows promise in late-stage lung cancer trial]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/n-OKTVmV2MYjvzmYffaF1KvFLgk=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/T6JXUKI575M6VERUPT3S52CI2Y.jpg" style="width: 100%;" /><div>AstraZeneca said on Thursday a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with an aggressive form of lung cancer, when given before surgery.</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-says-imfinzi-combo-shows-promise-late-stage-lung-cancer-trial-2022-06-30/</link><guid isPermaLink="false">8127c2636e8dce0ca3c7519598695e06</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Thu, 30 Jun 2022 18:03:18 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/n-OKTVmV2MYjvzmYffaF1KvFLgk=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/T6JXUKI575M6VERUPT3S52CI2Y.jpg"/></item><item><title><![CDATA[Pfizer asks for formal U.S. approval of oral COVID treatment Paxlovid]]></title><description><![CDATA[<div><img src="https://www.reuters.com/resizer/_iUsKtwwEo6KIwN8YaLX362ildk=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/53HHGVRZUFLLBHIRJNCBPT6RDY.jpg" style="width: 100%;" /><div>Pfizer Inc said on Thursday it is seeking full U.S. approval for its oral COVID-19 antiviral treatment Paxlovid, which is currently available under an emergency use authorization (EUA).</div></div>]]></description><link>https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-asks-formal-us-approval-oral-covid-treatment-paxlovid-2022-06-30/</link><guid isPermaLink="false">364c064036c770a1f7d8e8490daeaaac</guid><dc:creator><![CDATA[Reuters]]></dc:creator><pubDate>Thu, 30 Jun 2022 17:36:36 GMT</pubDate><media:content medium="image" url="https://www.reuters.com/resizer/_iUsKtwwEo6KIwN8YaLX362ildk=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/53HHGVRZUFLLBHIRJNCBPT6RDY.jpg"/></item></channel></rss>